ArticleScientific reports2025
Evaluating the efficacy of neoadjuvant immunotherapy combined with chemotherapy for stage IIIa non-small cell lung cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis for stage IIIa non-small cell lung cancer (NSCLC) remains poor, necessitating innovative treatment strategies to improve patient outcomes. This study evaluates the efficacy of neoadjuvant immunotherapy combined with chemotherapy in enhancing resection rates, survival, and progression-free survival in patients with stage IIIa NSCLC. A retrospective analysis was conducted on 82 patients treated at The Third People's Hospital of Zhengzhou, Henan, China, between October 2018 and April 2019. Patients were divided into two groups: an experimental group (n = 41) treated with a combination of platinum-based chemotherapy (pemetrexed and nedaplatin) and the PD-1 inhibitor cindilizumab, and a control group (n = 41) treated with conventional platinum-based chemotherapy. The experimental group demonstrated a significantly higher objective response rate, superior R0 resection rates, and fewer metastatic lymph nodes compared to the control group. Postoperative complications were significantly reduced in the experimental group, accompanied by substantial reductions in tumor markers, including cytokeratin 19 fragments and carbohydrate antigen 125. Median overall survival and progression-free survival were longer in the experimental group than in the control group. Hematological safety was confirmed with no significant differences in routine blood counts between the two groups before or after treatment. These findings support the integration of neoadjuvant immunotherapy and chemotherapy as a promising strategy for treating stage IIIa NSCLC, offering improved resection rates, survival, and reduced complications. Further research is warranted to optimize treatment protocols and validate these results in larger, multicentre studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.